STUDY REPORT

TREATMENT OF INSOMNIA WITH ENERGETIC ACUPUNCTURE POINT ACTIVATION

A DOUBLE-BLIND PLACEBO RANDOMIZED TRIAL

Protocol number: SN2011-002

Investigational products:
- LifeWave Silent Nights patches
- Placebo patches

Form(s):
Non-transdermal patches

Application(s):
Application on acupuncture points

Location of study site
Shealy Wellness Center
5607 S. 222nd Road
Fair Grove, MO 65648
United States

Principal Investigator:
Dr. C. Norman Shealy, M.D., Ph.D.

Sponsor:
LifeWave Inc
Dr. Steve Haltiwanger, MD, CCN
Health and Science Director
1020 Prospect St. Suite 200
La Jolla, Ca. 92037
United States

Date and report version number:
Final Version 1.0

Confidentiality
This report is the property of the sponsor. The information contained in this report may not be disclosed in whole or in part, submitted for publication, or form the basis for an industrial property licence without prior written approval from the sponsor. Persons to whom this information is supplied for any purposes must be informed that it is confidential and must not be disclosed.
SPONSOR SIGNATURES IN ACCORDANCE WITH THE REPORT

SPONSOR

Dr. Steve Haltiwanger, MD
Health and Science Director

10/29/12 Date

Signature

PRINCIPAL INVESTIGATOR SIGNATURES IN ACCORDANCE WITH THE REPORT

Dr. C. Norman Shealy, M.D., Ph.D.
Principal investigator

9/12/12 Date

Signature

Signature

Dermscan

PRM03-F-077_A
CLINICO STATISTICAL REPORT

Date: 04/04/2012
Version: 2
## SYNOPSIS

<table>
<thead>
<tr>
<th>Study number:</th>
<th>SN2011-002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol Title:</td>
<td>Treatment of insomnia with energetic acupuncture point activation. A double-blind placebo randomized trial</td>
</tr>
<tr>
<td>Sponsor:</td>
<td>LIFEWAVE Inc.</td>
</tr>
</tbody>
</table>
| Objectives: | **Main objective:** To evaluate the effectiveness of LifeWave Silent Nights® patches on quality and depth of sleep.  
**Secondary objective** To evaluate the LifeWave Silent Nights® patches safety. |
| Design: | Phase 1: double-blind, controlled-placebo study. During two weeks (D0-D14), subjects were randomly divided in two groups:  
- One group receiving the active patches  
- One group receiving the placebo patches.  
Phase 2: open study  
After phase 1, all subjects received active patches during 4 weeks. |
| Sample Size: | 50 subjects included.  
46 subjects analysed. |
| Number of centers: | One center |
| Inclusion criteria: | 1. Subjects willing to participate by signing a voluntary informed consent.  
2. Subjects with the ability and willingness to follow the instructions of the Principal Investigator (PI) and the research staff.  
3. Subjects in reasonably good health and without any major illness, not being on any beta blockers, antidepressants or tranquilizers.  
4. Insomnia for a minimum of 3 months with average sleep length less than 6 hours. |
| Exclusion criteria: | 1. Subjects with an implanted electronic device.  
2. Subjects with major medical illnesses.  
3. Subjects on beta blockers, tranquilizers or antidepressants.  
4. Subjects who drank caffeinated beverages after 3 PM  
5. Not more than 10 of the 50 potential subjects smokers.  
| Investigational product: | **Name / code:** LifeWave Silent Nights patches  
**Galenic form:** Non- transdermal patches system (Class I medical device) |
| Placebo | **Name / code:** Placebo patches  
**Galenic form:** Non- transdermal patches system (Class I medical device) |
### Dosage:
- **Dosage:** NA

### Duration:
- **Duration:** One application by day at bedtime.

### Administration route:
- **Administration route:** Cutaneous application on acupuncture points (non-transdermal patches)

### Safety Parameters:
- **Safety Parameters:** Analysis of adverse events and adverse reactions.

### Efficacy Parameters:
- **Sleep Analog Scale** (subject’s estimate of average length of sleep).
- **Pittsburgh Sleep Quality Index:** the Pittsburgh Sleep Quality Index (PSQI).
- **Leeds Sleep Evaluation Questionnaire.**
- **Epworth-Sleepiness Scale.**
- **Total Symptom Index.**

### Statistics:
- **Statistics:** To assess the change from baseline at each time point, a paired t-test was used. To compare active and placebo groups, a t-test for unpaired data was used. The normality assumption was checked with a Shapiro-Wilk test ($\alpha=0.01$). In case of deviation, a Wilcoxon signed rank test or Mann-Whitney was applied instead.

### Results-Conclusion
- **Results-Conclusion**
  - After 2 weeks of patches use, the active group improved sleep by 2.22 hours whereas the placebo group improved sleep by 0.98 hours in the same period. So the sleep improvement in the active patch group was 1.24 hours more than the placebo group. The difference between active and placebo groups was statistically significant ($p=0.048$).
  - At the end of the next 4 weeks, length of sleep in both groups receiving the active patches increased 2.53 hours in average ($p<0.001$) (66% of sleep increase).
  - No adverse reaction was observed. The patches can then be considered as well tolerated.
  - Considering the safety and results obtained in this study of LifeWave® Silent Nights Patches, it is reasonable to suggest that they should be one of the preferred potential approaches to insomnia.
3  TABLE OF CONTENTS

1  TITLE _____________________________________________ 1

2  SYNOPSIS ___________________________________________ 3

Secondary objective _______________________________________ 3

3  TABLE OF CONTENTS ___________________________________ 5

4  LIST OF ABBREVIATIONS AND DEFINITION OF TERMS _______ 7

5  ETHICS _______________________________________________ 8

5.1 Independent Ethics Committee or Institutional Review Board (IRB) ________ 8

5.2 Ethical conduct of the study _______________________________ 8

5.3 Subject information and consent form ______________________ 8

6  INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ______ 9

7  INTRODUCTION ________________________________________ 9

8  RESEARCH OBJECTIVES _______________________________ 10

8.1 Primary objective _____________________________________ 10

8.2 Secondary objective(s) __________________________________ 10

9  CONCEPTION OF THE RESEARCH ________________________ 10

9.1 Methodology of the research ______________________________ 10

9.2 Research Flow chart ___________________________________ 11

9.3 Description of the research schedule ______________________ 11

9.4 Discussion of research design, including the choice of control group ______ 12

9.5 Selection of the studied population ________________________ 12

9.5.1 Inclusion criteria ___________________________________ 12

9.5.2 Exclusion criteria ___________________________________ 12

9.5.3 Premature study exit _________________________________ 12

9.5.3.1 Criteria and modalities of premature end of treatment or subject exclusion from the study 12

9.5.3.2 Modalities for the follow-up of these subjects ____________ 13

9.6 Investigational products ________________________________ 13

9.6.1 Description of the investigational product(s) _______________ 13

9.6.2 Dosage ____________________________________________ 13

9.6.3 Instruction(s) of use _________________________________ 13

9.6.3.1 Administration route and recommendation(s) ___________ 13

9.6.3.2 Storage conditions ________________________________ 14

9.6.3.3 Dispensing and accountability of investigational product(s) ___________ 14

9.6.4 Treatments allocation – Randomisation - Blinding ____________ 14

9.7 Evaluation variables ____________________________________ 14

9.7.1 Evaluation criteria ___________________________________ 14

9.7.1.1 Main evaluation criterion _____________________________ 14

9.7.1.2 Secondary evaluation criteria __________________________ 14

9.7.2 Efficacy Evaluation ________________________________ 15

9.7.2.1 Description of the efficacy parameters _________ 15

9.7.2.2 Method and calendar for measure, collect and analyze the efficacy parameters ________ 16

9.7.3 Safety Evaluation ________________________________ 16

9.7.3.1 Description of the safety parameters ___________________ 16
9.7.3.2 Method and calendar for measure, collect and analyze the safety parameters 16

9.8 Data Quality Assurance – Monitoring 17
9.8.1 Collection and data control 17
9.8.2 Access right to source data 17

9.9 Statistics 17

9.10 Administrative Procedures 17
9.10.1 Archiving of study data and documents 17
9.10.2 Audit and inspection 17
9.10.3 Publication 17

10 STUDY SUBJECTS 18

10.1 Disposition of subjects 18
Four subjects (17, 24, 25 and 29) dropped out during the study. 18

10.2 Protocol deviations 18

11 EFFICACY EVALUATION 19

12 SAFETY EVALUATION 21
12.1 Extent of Exposure 21
12.2 Adverse reactions 21
12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events 21
12.4 Clinical laboratory results 21
12.5 Safety conclusions 21

13 DISCUSSION AND OVERALL CONCLUSION 22

14 TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT 23

15 REFERENCES LIST 23
15.1 Ethical aspect 23
15.2 Insomnia and investigational product 23

16 APPENDICES 24
16.1 General description of the research 24
16.1.1 Protocol and amendments 24
16.1.2 Blank Case Report Form 24
16.1.3 List of CPP (or IRB) with the name of the president if required by the competent authority 24
16.1.4 Blank information and consent form 24
16.1.5 List and identification of the investigators and important personal participating in the study 24
16.1.6 Listing of subjects receiving investigational product(s) from specific batches where more than one batch was used 24
16.1.7 Randomisation scheme and codes (subject identification and treatment assigned) 25
16.1.8 Audit certificates (if available) 25
16.1.9 Documentation of statistical methods 25
16.1.10 Documentation of inter-laboratory standardisation methods and quality assurance procedures if used 26
16.1.11 Publications based on the research 26
16.1.11.1 PITTSBURGH SLEEP QUALITY INDEX 26
16.1.11.2 Leeds Sleep Evaluation Questionnaire 28
16.1.11.3 Epworth-Sleepiness Scale 28

16.2 Subject data listings 30
16.3 Case report forms

16.3.1 CRFs of deaths, other serious adverse events and withdrawals for AE

16.3.2 Other CRFs submitted

16.4 Other Individual subject data listings (US Archival Listings)

4 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical Research Associate</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>I.C.H</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>MD</td>
<td>Medical Device</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>PSQI</td>
<td>Pittsburgh Sleep Quality Index</td>
</tr>
</tbody>
</table>
5 ETHICS

5.1 Independent Ethics Committee or Institutional Review Board (IRB)

The protocol and its appendices were reviewed and approved by the Quantum Institutional Review Board (USA) on March 24, 2011.

5.2 Ethical conduct of the study

Declaration of HELSINKI (1)

The current revision of the Declaration of Helsinki is the accepted basis for clinical study ethics, and must be fully followed and respected by all engaged in research on human beings. Any exceptions must be justified and stated in the protocol. Independent insurance that subjects are protected can only be provided by an ethics committee/institutional review board and freely obtained informed consent.

Good Clinical Practice (2)

Good clinical practice is a standard for clinical studies, which encompasses the design, conduct, monitoring, termination, audit, analyses, reporting and documentation of the studies. It ensures the studies are ethically justified and scientifically sound, and that the clinical properties of the diagnostic/therapeutic/prophylactic product under investigation are properly documented.

Ethics Committee or IRB (3)

It is the responsibility of the sponsor or its legal representative to submit a copy of the protocol and detailed patient information sheet and consent form to an ethics committee/institutional review board in order to obtain independent approval to conduct the study. Ethics committee/institutional review board approval must be obtained before the study is started. The approval of the ethics committee/institutional review board must be sent in writing, to the sponsor or its legal representative. The Ethics Committee approval letter must mention the Ethics Committee members and their function.

This clinical study was conducted on subjects in accordance with Good Clinical Practice (GCP) (ICH Topic E6 Note for Guidance on GCP CPMP/ICH/135/95, ISO1455 standard).

5.3 Subject information and consent form

It is the responsibility of the investigator(s) to obtain informed consent from each subject participating in the study, after explanation of the aims, methods, benefits and potential hazards of the study.

It should be completely and unambiguously clear to each subject that she/he is free to refuse to participate in the study, or that she/he can withdraw her/his consent at any time and for any reason, without incurring any penalty or withholding of treatment on the part of the investigator.

The consent obtaining should be done under such conditions that permit to the subject to consider in the best way the ratio benefits/risks associated to his/her participation in the study.

The investigator insures that the content of the information and consent form is appropriate to the study and that the process for obtaining the consent is in conformity with the applicable regulation.

In the frame of this study, the consent has been obtained before any study-specific procedures were performed, and thus in accordance with the Helsinki declaration.

No subject could be included and/or randomized before having signed the consent form, written in an understandable language.

Each subject received oral and written information concerning the studied product(s), its nature, the duration and the conditions of the study. The consent was personally signed and dated by the subject in two exemplars and by the person in charge of the consent obtaining.
6 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

The study was conducted on Shealy Wellness Center (5607 S. 222nd Road, Fair Grove, MO 65648, United States).

The list of the main participants in the study is presented in Appendix 16.1.4.

7 INTRODUCTION

Just over 200 years ago, most Americans slept an average of 10 hours, adjusting their wake-sleep hours to daylight. Today a huge number of individuals sleep not more than 5.5 hours per night and they do not consider that a sleep problem. In a number of surveys, 40% of individuals report that they have significant problems with insomnia.1 There are excellent studies showing that within a month or less, insomnia leads to excessive sleepiness at work, mood disturbances, increase in errors, increase in accidents and family and social problems. Chronic insomniacs have a much higher incidence of cardiovascular disease, diabetes, obesity, gastrointestinal disease, absenteeism, disciplinary problems, separation, divorce and death. The problems and the incidence of illness in general markedly increase in individuals who work anything other than a normal 8 to 5 pattern. Those who work the evening shift, roughly 4 p.m. to midnight, have increased illnesses and those who work the night shift, roughly midnight to 8 a.m. or 11 p.m. to 7 a.m., have an even greater number of illnesses. And finally, those who have swing shifts, working one month one shift and the next month a different shift, have the greatest number of illnesses of all.2-8

There are a number of medications that have been used to treat insomnia. None of these is totally satisfactory and all of them carry significant potential, and often “undesirable,” side effects. Benzodiazepines are particularly harmful as they interfere with stage 4 sleep. Antidepressant drugs most often also have many undesirable effects when used only to treat insomnia. Finally, the drugs specifically for sleep often lead to the feeling of a hangover or sleep walking, driving and other activities while asleep, and even modest use of hypnotic sleep prescriptions leads to marked increase in the risk of death.9

In the current study, our objective is to determine the potential for safe and effective enhancement of sleep with the application of specific acupuncture patches designed to improve sleep.

LifeWave Patches are designed to stimulate acupuncture points by a mechanism that involves both acupressure and energetic principles to stimulate specific acupuncture points.

Initially, under an Institutional Review Board approved protocol, 25 individuals suffering from long-standing insomnia were entered into an open-label study. The LifeWave Patches are comprised of solutions of optically active organic material, which serve as organic molecular antennae (nano-sized molecular structures) using a solution based self-regulation process. All subjects were in reasonably good health with no major illnesses and were not on beta blockers, antidepressants or tranquilizers. None of them had an implanted electronic device. After initial evaluation, which consisted of a history and physical exam, participants completed the following questionnaires: Pittsburgh Sleep Quality Index, Leeds Sleep Evaluation Questionnaire, Epworth-Sleepiness Scale, Sleep Analog Scale. Individuals were instructed to place one of the patches on 1 of 5 specific acupuncture points at bedtime. If individuals did not sleep adequately the first night, they could go through each of these points until they had achieved the best possible sleep and then rotate between the points that had the best effect for the duration of the 30 day study. One individual dropped out of the study and could not be contacted for further evaluation. There were no negative reports. The results showed that seventy-two percent of the individuals had normal daytime sleeping (ESS Test) after using the Silent Nights patches. Eighty percent noted improved quality of sleep (LESQ Test) and 88% had improved length of sleep (PSQ Test). In general, the PSQ Test and the Sleep Analog yielded equal results.

Following this, a follow-up study was designed as a double blind/placebo controlled randomized study of the Silent Nights patches.
8 RESEARCH OBJECTIVES

8.1 Primary objective

The main objective of the study was to evaluate the effectiveness of LifeWave Silent Nights® patches on quality and depth of sleep.

8.2 Secondary objective(s)

The secondary objective of the study was to evaluate the LifeWave Silent Nights® patches safety.

9 CONCEPTION OF THE RESEARCH

9.1 Methodology of the research

There was two phases in the study

Phase 1: double-blind, controlled-placebo study.

During two weeks (D0-D14), subjects were randomly divided in two groups:
- One group receiving the active patches
- One group receiving the placebo patches.

Phase 2: open study
After phase 1, all subjects received active patches during 4 weeks.
9.2 Research Flow chart

Figure 1 - Study flow chart

<table>
<thead>
<tr>
<th>Schedule</th>
<th>Visit 1</th>
<th></th>
<th></th>
<th>Visit 2</th>
<th>Visit 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Screening/Inclusion</td>
<td>Evaluation</td>
<td>Evaluation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days</td>
<td>D0</td>
<td>D14 ± 1</td>
<td>D42 ± 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent form signature</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical examination</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Checking of the inclusion and exclusion criteria</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch distribution (active or placebo) for the first part of the study</td>
<td>■</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patch distribution (active) for the second part of the study</td>
<td></td>
<td>■</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep scales completion by the subjects</td>
<td>■</td>
<td>■</td>
<td>■</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AE collection</td>
<td></td>
<td>■</td>
<td>■</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study end</td>
<td></td>
<td></td>
<td>■</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9.3 Description of the research schedule

Screening/inclusion visit:
- Subjects were recruited on a weekly radio program, which the lead author has done for 22 years. They were informed over the phone about the details of the study and an appointment was made.
- Subjects came to the study site. They were orally informed about study aims, restrictions and risks, and then, in writing by the informed consent form. If they agreed to participate to this study, they signed the informed consent form in duplicate.
- They underwent a general medical evaluation and physical examination, which included a medical history, general physical and neurological exam. Inclusion and exclusion criteria were checked.
- Eligible subjects were then assigned a Subject ID and randomized to a treatment group for the two week, placebo-controlled portion of the study.
- Subjects completed the different sleep scales.
- Active or Placebo patches were given to the subjects according to a randomization list. Neither the subject nor the investigators knew which patch was attributed to each subject (double-blind study).
- Subjects were instructed to use one of the five placements as in the previous pilot study and to proceed with all variations until they found the best personal preferred location.

After 2 weeks (D14):
- Subjects returned to the study site.
- Possible adverse events were collected.
- They completed the different sleep scales.
- All subjects were provided with active patches to be used for the next 4 weeks, as part of the open-label portion of the study.

After 4 additional weeks (D42):
- Subjects returned to the study site.
- Possible adverse events were collected.
- They completed the different sleep scales.
Remark: when considered appropriate for the study, subjects were shown how to use the patches and given an initial 15-day supply. Each individual was then given instructions to phone us if any concerns or side-effects developed, and were scheduled to return for repeat tests at the end of 14 or 15 days. They returned after two weeks and were given the other set of active patches and returned at the end of another 28 to 30 days for final testing.

9.4 Discussion of research design, including the choice of control group

The placebo controlled phase (phase 1) enables to experiment the placebo effect and to compare it to the active patches effect. The open phase (phase 2) enables to increase the number of subjects receiving the active patches.

9.5 Selection of the studied population

9.5.1 Inclusion criteria

1. Subjects willing to participate by signing a voluntary informed consent.
2. Subjects with the ability and willingness to follow the instructions of the Principal Investigator (PI) and the research staff.
3. Subjects in reasonably good health and without any major illness, not being on any beta blockers, antidepressants or tranquilizers.
4. Insomnia for a minimum of 3 months with average sleep length less than 6 hours.

9.5.2 Exclusion criteria

1. Subjects with an implanted electronic device.
2. Subjects with major medical illnesses.
3. Subjects on beta blockers, tranquilizers or antidepressants.
4. Subjects who drank caffeinated beverages after 3 PM
5. Not more than 10 of the 50 potential subjects smokers.

9.5.3 Premature study exit

9.5.3.1 Criteria and modalities of premature end of treatment or subject exclusion from the study

Subjects were free to withdraw from the study at any time if they wish so and for any reason, without having to provide any justification to the investigator.

The investigator had the right to withdraw a subject for any reason, for subject’s best interests, including illness or adverse events.

The sponsor may decide to withdraw subjects for major deviation to the protocol, for administrative reasons or for any other valuable reason ethically justified.

Subjects may discontinue the study for the following reasons:

1. Subject consent withdrawal: subjects had the right to exit from the study at any time and for any motive, without their right to treatment being affected.
2. Medical reasons or adverse events: the investigator had the right to withdraw a subject in case of intercurrent illness or adverse events or if in the investigator’s opinion, continuation in the study would be detrimental to the subject's well-being.
3. Appearance of an exclusion criterion.
4. Failure to follow-up: if a subject did not come to the scheduled visits, several attempts had to be done to try to contact him/her; to obtain the reasons for non-attendance.
5. Violations and deviations from the protocol.
6. Administrative reasons.
9.5.3.2 Modalities for the follow-up of these subjects

All records were maintained for subjects who drop out of the study and for subjects who were screened and failed to meet the study requirements. If a subject drops out within the first 2 weeks of the study, a replacement subject may be chosen and enrolled.

9.6 Investigational products

9.6.1 Description of the investigational product(s)

LifeWave technology creates a variety of patches using proprietary solutions of organic molecules as building blocks. LifeWave Patches are comprised of solutions of optically active organic materials. These special solutions are placed in a reservoir between two pieces of plastic, which create a sealed chamber. Within the sealed reservoir is a piece of fabric that serves as a template for the self assembly of organic molecular antennas (nano-sized molecular structures) using solution-based self-assembly processes, molecules that are nanometers in size. The production of small molecular antennas of nanoscale size is the nanotechnology aspect of this technology. The fact that the production of LifeWave patches involves making a solution, using proprietary processing techniques and using a special piece of fabric to cause a precipitation out of solution of nano-sized molecular crystals, does not in anyway detract from the fact that this is a nanotechnology manufacturing technique.

LifeWave patches are constructed of organic materials. These organic materials have been chosen because they have optical (chiral), liquid crystal and semiconductor properties. By using a nanotechnology production process called solution-based self-assembly, these optically active and electrically conductive materials, when placed in LifeWave patches, form small nanosize molecular structures that function as molecular antennas. Placing a conducting material in an oscillating magnetic field creates an electrical signal/frequency in the conducting material.

The "very small" molecules in the patches contain electromagnetic properties. These small nanoscale structures serve as passive molecular antennas that are activated by the oscillating electromagnetic field of the body to generate electromagnetic signals that are resonant frequencies for certain structures contained within molecules. THE BASIC ISSUE IS THAT YOU CAN ACTIVATE METABOLIC REACTIONS WITH FREQUENCY SIGNALS AS WELL AS CHEMICAL SIGNALS, IF YOU HAVE THE PROPER FREQUENCY CODE AND WAVEFORM. LifeWave patches basic function is to generate a set of biologically active signals when the patches interact with the human body’s mammalian cells. These frequencies are generated by the physics principle of INDUCTION. The patches chosen for this study will be those designed to enhance sleep.

9.6.2 Dosage

Patches were used daily during the whole study.

9.6.3 Instruction(s) of use

9.6.3.1 Administration route and recommendation(s)

Subjects were instructed to place one of the patches on 1 of 5 specific acupuncture points at bedtime.

The points used were:
- Right Liver
- Right Triple Heater
- Right Triple Heater
- Governing Vessel
- Right Stomach
If individuals did not sleep adequately the first night, they could go through each of these points until they had achieved the best possible sleep and then rotate between the points that had the best effect for the duration of the study.

9.6.3.2 Storage conditions

The study products were stored under the supervision of a physician approved for the study under suitable safety conditions ensuring proper storage. The active and inactive patches were kept in separate Faraday cages to avoid any possible energetic interchange between them.

The products were used only under conditions defined in this protocol and only for included subjects.

9.6.3.3 Dispensing and accountability of investigational product(s)

The tested products should only be dispensed under the supervision of a physician approved for the study. The investigator (or delegate) was responsible for dispensing the study products to the subjects who were included in the study. The study products should not be administered to subjects who were not included in the study.

9.6.4 Treatments allocation – Randomisation - Blinding

An assistant, not involved in patient care, received the prepared study articles from the Sponsor and placed the placebo and active patches for the first two weeks in Faraday cages in separate rooms. The study articles were coded upon arrival to indicate difference between the two treatments; however which treatment the code indicated was not known. The assistant used a randomized system to determine which initial patch was to be given a patient. The investigator had no contact with or knowledge about the selection of the patches.

9.7 Evaluation variables

9.7.1 Evaluation criteria

9.7.1.1 Main evaluation criterion

• Sleep Analog Scale is subject’s estimate of average length of sleep.

9.7.1.2 Secondary evaluation criteria

• Pittsburgh Sleep Quality Index: the Pittsburgh Sleep Quality Index (PSQI).
• Leeds Sleep Evaluation Questionnaire.
• Epworth-Sleepiness Scale.
• Total Symptom Index.
9.7.2 Efficacy Evaluation

9.7.2.1 Description of the efficacy parameters

9.7.2.1.1 Sleep Analog Scale

Sleep Analog is defined as the estimation by the subject of his/her average length of sleep.

9.7.2.1.2 Pittsburgh Sleep Quality Index

The Pittsburgh Sleep Quality Index (PSQI) was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers.

The questionnaire used for the PSQI evaluation is presented in appendix 16.1.13.1.

The PSQI score calculation is presented below:

**PSQIDURAT**  
**DURATION OF SLEEP**

- IF Q4 ≥ 7, THEN set value to 0
- IF Q4 < 7 and ≥ 6, THEN set value to 1
- IF Q4 < 6 and ≥ 5, THEN set value to 2
- IF Q4 < 5, THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIDISTB**  
**SLEEP DISTURBANCE**

- IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0) = 0, THEN set value to 0
- IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0) > 1 and ≤ 9, THEN set value to 1
- IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0) > 9 and ≤ 18, THEN set value to 2
- IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM is null or Q5j is null, set the value of Q5j to 0) > 18, THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQILATEN**  
**SLEEP LATENCY**

First, recode Q2 into Q2new thusly:

- IF Q2 > 0 and ≤ 15, THEN set value of Q2new to 0
- IF Q2 > 15 and ≤ 30, THEN set value of Q2new to 1
- IF Q2 > 30 and ≤ 60, THEN set value of Q2new to 2
- IF Q2 > 60, THEN set value of Q2new to 3

Next

- IF Q5a + Q2new = 0, THEN set value to 0
- IF Q5a + Q2new ≥ 1 and ≤ 2, THEN set value to 1
- IF Q5a + Q2new ≥ 3 and ≤ 4, THEN set value to 2
- IF Q5a + Q2new ≥ 5 and ≤ 6, THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIDAYDYS**  
**DAY DYSFUNCTION DUE TO SLEEPINESS**

- IF Q8 + Q9 = 0, THEN set value to 0
- IF Q8 + Q9 ≥ 1 and ≤ 2, THEN set value to 1
- IF Q8 + Q9 ≥ 3 and ≤ 4, THEN set value to 2
- IF Q8 + Q9 ≥ 5 and ≤ 6, THEN set value to 3

Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIHSE**  
**SLEEP EFFICIENCY**
### CLINICO-STATISTICAL REPORT

**Date:** 04/04/2012  
**Version:** 2  
**Page:** 16/32

**LifeWave Inc Test product: LifeWave Silent Nights patches**  
Study #: SN2011-002  
Final Report version 1.0  
Confidential

---

\[ \text{Diffsec} = \text{Difference in seconds between day and time of day Q1 and day Q3} \]
\[ \text{Diffhour} = \text{Absolute value of diffsec / 3600} \]
\[ \text{newtib} = \begin{cases} \text{IF diffhour} > 24, & \text{then newtib} = \text{diffhour} - 24 \\ \text{IF diffhour} \leq 24, & \text{THEN newtib} = \text{diffhour} \end{cases} \]

*(NOTE, THE ABOVE JUST CALCULATES THE HOURS BETWEEN GNT (Q1) AND GMT (Q3))*

\[ \text{tmphse} = (Q4 / \text{newtib}) \times 100 \]

\[ \begin{align*} 
\text{IF tmphse} & \geq 85, \text{THEN set value to 0} \\
\text{IF tmphse} & < 85 \text{ and } \geq 75, \text{THEN set value to 1} \\
\text{IF tmphse} & < 75 \text{ and } \geq 65, \text{THEN set value to 2} \\
\text{IF tmphse} & < 65, \text{THEN set value to 3} 
\end{align*} \]

*Minimum Score = 0 (better); Maximum Score = 3 (worse)*

**PSQISLPQUAL**  
OVERALL SLEEP QUALITY

Q6  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQIMEDS**  
NEED MEDS TO SLEEP

Q7  
Minimum Score = 0 (better); Maximum Score = 3 (worse)

**PSQI**  
TOTAL

\[ \text{DURAT} + \text{DISTB} + \text{LATEN} + \text{DAYDYS} + \text{HSE} + \text{SLPQUAL} + \text{MEDS} \]

Minimum Score = 0 (better); Maximum Score = 21 (worse)

Interpretation:  
TOTAL \leq 5 associated with good sleep quality  
TOTAL > 5 associated with poor sleep quality

---

### 9.7.2.1.3 Leeds Sleep Evaluation Questionnaire

The Leeds Sleep Evaluation Questionnaire comprises ten self-rating 100-mm-line analogue questions concerned with aspects of sleep and early morning behaviour. The Leeds Sleep Evaluation Questionnaire is presented in Appendix 16.1.13.2.

### 9.7.2.1.4 Epworth-Sleepiness Scale

The Epworth Sleepiness Scale (ESS) is a scale intended to measure daytime sleepiness that is measured by use of a very short questionnaire. This questionnaire is presented in Appendix 16.1.13.2.

### 9.7.2.1.5 Total Symptom Index

Although this has not been evaluated in relation to sleep, it has been shown to correlate with total stress.

### 9.7.2.2 Method and calendar for measure, collect and analyze the efficacy parameters

All the sleep scales were completed by the subjects at baseline, after two weeks of placebo or active patches use, and after 4 additional weeks of active patches use.

### 9.7.3 Safety Evaluation

#### 9.7.3.1 Description of the safety parameters

Safety of the patches was evaluated by collection of possible adverse reactions.

#### 9.7.3.2 Method and calendar for measure, collect and analyze the safety parameters

Adverse events were collected at each visit after the baseline.
9.8 Data Quality Assurance – Monitoring

9.8.1 Collection and data control

At each visit of the subject, the investigator reported in the CRF the data related to the subject’s health state, safety of the products applied and scores of each sleep scale, according to the protocol within the study.

The case report forms were designed to identify each subject by a subject number and, where appropriate, subject's initials. One Case Report Form existed for each subject participating in the study. The case report form was completed legibly, using a black ballpoint pen. Erroneous values and/or text were not erased. Instead, the error was crossed out with a single line, the correct value/text added, and the correction signed, initialled and dated by the investigator(s).

9.8.2 Access right to source data

In accordance with good clinical practices and the standards of the data protection law, data obtained in the course of a biomedical research has to be treated confidentially to guarantee the subjects’ privacy.

The investigator agreed that, subject to local regulations and ethical considerations, the sponsor representatives designee and/or any regulatory agency may have direct access to all study records, CRFs, corresponding subject medical records, study drug dispensing records and study drug storage area, and any other documents considered source documentation. The investigator also agreed to assist the representative, if required.

9.9 Statistics

To assess the change from baseline at each time point, a paired t-test was used. To compare active and placebo groups, a t-test for unpaired data was used. The normality assumption was checked with a Shapiro-Wilk test (\( \alpha = 0.01 \)). In case of deviation, a Wilcoxon signed rank test or Mann-Whitney was applied instead.

9.10 Administrative Procedures

9.10.1 Archiving of study data and documents

Study data will be kept by the researcher in locked files for 5 years.

9.10.2 Audit and inspection

The study was conducted under the responsibility of the sponsor in compliance with the applicable international and local regulatory requirements and in respect of the sponsor and/or CRO SOPs for study conduct and monitoring.

Inspection may be performed by regulatory authorities’ inspectorate before, during, or after the study.

9.10.3 Publication

The sponsor reserves the right to review all the manuscript(s) and abstract(s) before their submission for publication or presentation. Publication of data will be at the discretion of the sponsor.
10 STUDY SUBJECTS

10.1 Disposition of subjects

There were 50 subjects included: 31 women and 19 men, ranging in age from 18 to 80. Four subjects (17, 24, 25 and 29) dropped out during the study.

Phase 1 (double-blind study versus placebo):

<table>
<thead>
<tr>
<th>Number of subject initially included</th>
<th>Active</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>25</td>
<td>25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of subjects who ended the study after 2 weeks</th>
<th>Active</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>23</td>
<td>23</td>
</tr>
</tbody>
</table>

Phase 2 (open study):

<table>
<thead>
<tr>
<th>Number of subject at the beginning of phase 2</th>
<th>Active</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>46</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of subjects who ended the study after 4 weeks</th>
<th>Active</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>46</td>
</tr>
</tbody>
</table>

10.2 Protocol deviations

No deviation occurred.
11 Efficacy Evaluation

There were no significant differences in the Sleep Inventories, perhaps because of the wide variation in the initial testing. Only the Sleep Analog (number of hours of sleep), which had been shown to be as accurate as the length of sleep in the Pittsburgh Sleep Quality Index in the open label study, showed significant increases in length of sleep, and is presented in this report.

The individual data of Sleep Analog are presented in Appendix 16.2.

Phase 1: double-blind study versus placebo

The results are summarized in the table below:

<table>
<thead>
<tr>
<th></th>
<th>Initial</th>
<th>After 2 weeks</th>
<th>Difference</th>
<th>Student t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silent Nights patches (n=23)</td>
<td>3.93 ± 0.21</td>
<td>6.15 ± 0.39</td>
<td>2.22 ± 0.41</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Placebo (n=23)</td>
<td>3.76 ± 0.32</td>
<td>4.74 ± 0.38</td>
<td>0.98 ± 0.45</td>
<td>p=0.039</td>
</tr>
</tbody>
</table>

The active group improved sleep by 2.22 hours after the 2nd week compared to baseline whereas the placebo group improved sleep by 0.98 hours in the same period. So the sleep improvement in the active patch group was 1.24 hours more than the placebo group. The difference between active and placebo groups was statistically significant (p=0.048).

Results are illustrated in the graph below:
Phase 2: open study

At the end of the 2 week period, the placebo group received the active treatment as well.

Average number of sleep by night (mean ± SEM)

<table>
<thead>
<tr>
<th></th>
<th>Initial</th>
<th>Final</th>
<th>Difference</th>
<th>Student t-test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silent Nights patches</td>
<td>3.93 ± 0.21</td>
<td>6.15 ± 0.32</td>
<td>2.22 ± 0.35</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>(n=23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>3.76 ± 0.32</td>
<td>6.61 ± 0.45</td>
<td>2.85 ± 0.45</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>(n=23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>3.85 ± 0.19</td>
<td>6.38 ± 0.28</td>
<td>2.53 ± 0.29</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>(n=46)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

When we examine the placebo group’s increase in numbers of hours asleep at final compared to baseline (when they were wearing active patches for the last 4 weeks) we find 2.85 hours longer sleep.

When we examine the active group’s increase in numbers of hours asleep at final compared to baseline (when they were wearing active patches for the last 4 weeks), we find 2.22 hours longer sleep.

Taking the whole together, we find that use of active LifeWave patches in all 46 people (who used active patches for the last 4 weeks increased sleep length of 2.53 hours in average (p<0.001) (66% of sleep increase).

This is a significant number to sleep over 2 and one-half hours longer with use of the patches.

Results are illustrated in the graph below:
12 SAFETY EVALUATION

12.1 Extent of Exposure

23 subjects tested the active patches during 6 weeks.
23 subjects tested the placebo patches during 2 weeks and then the active patches during 4 weeks.

No subject stopped the treatments following intolerance reactions.

12.2 Adverse reactions

No adverse reactions occurred during the study.

12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

Not applicable.

12.4 Clinical laboratory results

Not applicable.

12.5 Safety conclusions

Both active and placebo patches can be considered as very well tolerated.
13 DISCUSSION AND OVERALL CONCLUSION

The results in the open label and the randomized double-blind placebo controlled study are remarkably similar, with only 8% less increase in length of sleep in the placebo-controlled study. There were no complications or adverse effects in either study. The subjects in this study started with an average sleep length of 2 to 5.5 hours, with one exception of 7 hours. Those receiving active patches entered with 3.9 hours average length of sleep. At the end of the first 2 weeks, they were sleeping an average of 6.2 hours and after another 4 weeks they were still sleeping an average of 6.2 hours. Those receiving placebo patches initially entered with average length of sleep from one to 5 hours. Those who initially received placebo patches entered sleeping an average of 3.8 hours. At the end of the first two weeks, they averaged 4.7 hours and after 4 weeks using the active patches, they averaged 6.6 hours of sleep.

There are several other studies of LifeWave technology including one that showed marked improvement in heart rate variability signals, of LifeWave Energy Patches during rest and exercise in 20 young and healthy volunteers. Another study called “Nanoscale Wearable Devices Reduce Qualitative and Quantitative Measures of Neuromuscular Pain”, which was published in the International Journal of Medical Implants & Devices, demonstrated a highly significant reduction in quantitative and qualitative measures of pain with an average statistical power of at least 94% and significant at the greater than 0.001 level. Thus, there appears to be increasing evidence that these energetic acupuncture patches have physiological effects. Considering the safety and results obtained in this study of LifeWave® Silent Nights Patches, it is reasonable to suggest that they should be one of the preferred potential approaches to insomnia.
14 **TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT**

Not applicable.

15 **REFERENCES LIST**

15.1 **Ethical aspect**

1. WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI/ Ethical Principles for Medical Research Involving Human Subjects- Helsinki Declaration (1964) and its successive updates

2. ICH TOPIC E6/ Note for guidance on Good Clinical Practice- CPMP / ICH / 135 / 95, January 1997

15.2 **Insomnia and investigational product**


16  APPENDICES

16.1  General description of the research

16.1.1  Protocol and amendments
Not included.

16.1.2  Blank Case Report Form
Not included.

16.1.3  List of CPP (or IRB) with the name of the president if required by the competent authority
Not included.

16.1.4  Blank information and consent form
Not included.

16.1.5  List and identification of the investigators and important personal participating in the study

<table>
<thead>
<tr>
<th>NAME</th>
<th>FUNCTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Norman Shealy, M.D., Ph.D.</td>
<td>Main investigator</td>
</tr>
<tr>
<td>Julie A. Penick, FNP, Ph.D</td>
<td>Co-investigator</td>
</tr>
<tr>
<td>Robert Mueller</td>
<td>Research Associate</td>
</tr>
</tbody>
</table>

16.1.6  Listing of subjects receiving investigational product(s) from specific batches where more than one batch was used
Not applicable.
16.1.7 Randomisation scheme and codes (subject identification and treatment assigned)

<table>
<thead>
<tr>
<th>Subject #</th>
<th>Product</th>
<th>Subject #</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Active</td>
<td>26</td>
<td>Active</td>
</tr>
<tr>
<td>2</td>
<td>Placebo</td>
<td>27</td>
<td>Placebo</td>
</tr>
<tr>
<td>3</td>
<td>Active</td>
<td>28</td>
<td>Active</td>
</tr>
<tr>
<td>4</td>
<td>Placebo</td>
<td>29</td>
<td>Placebo</td>
</tr>
<tr>
<td>5</td>
<td>Placebo</td>
<td>30</td>
<td>Active</td>
</tr>
<tr>
<td>6</td>
<td>Active</td>
<td>31</td>
<td>Active</td>
</tr>
<tr>
<td>7</td>
<td>Active</td>
<td>32</td>
<td>Placebo</td>
</tr>
<tr>
<td>8</td>
<td>Placebo</td>
<td>33</td>
<td>Active</td>
</tr>
<tr>
<td>9</td>
<td>Active</td>
<td>34</td>
<td>Placebo</td>
</tr>
<tr>
<td>10</td>
<td>Placebo</td>
<td>35</td>
<td>Active</td>
</tr>
<tr>
<td>11</td>
<td>Placebo</td>
<td>36</td>
<td>Placebo</td>
</tr>
<tr>
<td>12</td>
<td>Active</td>
<td>37</td>
<td>Placebo</td>
</tr>
<tr>
<td>13</td>
<td>Active</td>
<td>38</td>
<td>Active</td>
</tr>
<tr>
<td>14</td>
<td>Placebo</td>
<td>39</td>
<td>Active</td>
</tr>
<tr>
<td>15</td>
<td>Active</td>
<td>40</td>
<td>Placebo</td>
</tr>
<tr>
<td>16</td>
<td>Placebo</td>
<td>41</td>
<td>Placebo</td>
</tr>
<tr>
<td>17</td>
<td>Placebo</td>
<td>42</td>
<td>Placebo</td>
</tr>
<tr>
<td>18</td>
<td>Placebo</td>
<td>43</td>
<td>Active</td>
</tr>
<tr>
<td>19</td>
<td>Active</td>
<td>44</td>
<td>Active</td>
</tr>
<tr>
<td>20</td>
<td>Placebo</td>
<td>45</td>
<td>Placebo</td>
</tr>
<tr>
<td>21</td>
<td>Placebo</td>
<td>46</td>
<td>Active</td>
</tr>
<tr>
<td>22</td>
<td>Active</td>
<td>47</td>
<td>Active</td>
</tr>
<tr>
<td>23</td>
<td>Active</td>
<td>48</td>
<td>Placebo</td>
</tr>
<tr>
<td>24</td>
<td>Placebo</td>
<td>49</td>
<td>Placebo</td>
</tr>
<tr>
<td>25</td>
<td>Active</td>
<td>50</td>
<td>Active</td>
</tr>
</tbody>
</table>

16.1.8 Audit certificates (if available)
Not applicable.

16.1.9 Documentation of statistical methods
Not applicable
16.1.10 Documentation of inter-laboratory standardisation methods and quality assurance procedures if used

Not applicable.

16.1.11 Publications based on the research

16.1.11.1 PITTSBURGH SLEEP QUALITY INDEX

The following questions relate to your usual sleep habits during the past month only. Your answers should indicate the most accurate reply for the majority of days and nights in the past month. Please answer all questions.

1. During the past month, what time have you usually gone to bed at night?
   BED TIME __________

2. During the past month, how long (in minutes) has it usually taken you to fall asleep each night?
   NUMBER OF MINUTES __________

3. During the past month, what time have you usually gotten up in the morning?
   GETTING UP TIME __________

4. During the past month, how many hours of actual sleep did you get at night? (This may be different than the number of hours you spent in bed.)
   HOURS OF SLEEP PER NIGHT __________

For each of the remaining questions, check the one best response. Please answer all questions.

5. During the past month, how often have you had trouble sleeping because you . . .

a) Cannot get to sleep within 30 minutes
   Not during the past month _____ Once a week _____ a week _____ times a week _____

b) Wake up in the middle of the night or early morning
   Not during the past month _____ Once a week _____ a week _____ times a week _____

c) Have to get up to use the bathroom
   Not during the past month _____ Once a week _____ a week _____ times a week _____

   Page 2 of 4

d) Cannot breathe comfortably
   Not during the past month _____ Once a week _____ a week _____ times a week _____

e) Cough or snore loudly
   Not during the past month _____ Once a week _____ a week _____ times a week _____

f) Feel too cold
   Not during the past month _____ Once a week _____ a week _____ times a week _____

g) Feel too hot
   Not during the past month _____ Once a week _____ a week _____ times a week _____

h) Had bad dreams
   Not during the past month _____ Once a week _____ a week _____ times a week _____

i) Have pain
   Not during the past month _____ Once a week _____ a week _____ times a week _____
j) Other reason(s), please describe____________________________________________________

How often during the past month have you had trouble sleeping because of this?
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

6. During the past month, how would you rate your sleep quality overall?
Very good__________
Fairly good__________
Fairly bad__________
Very bad__________

7. During the past month, how often have you taken medicine to help you sleep (prescribed or
"over the counter")?
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

8. During the past month, how often have you had trouble staying awake while driving, eating
meals, or engaging in social activity?
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

9. During the past month, how much of a problem has it been for you to keep up enough
enthusiasm to get things done?
No problem at all__________
Only a very slight problem__________
Somewhat of a problem__________
A very big problem__________

10. Do you have a bed partner or room mate?
No bed partner or room mate__________
Partner/room mate in other room__________
Partner in same room, but not same bed__________
Partner in same bed__________
If you have a room mate or bed partner, ask him/her how often in the past month you
have had . . .
a) Loud snoring
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

b) Long pauses between breaths while asleep
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

c) Legs twitching or jerking while you sleep
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

d) Episodes of disorientation or confusion during sleep
Not during the Less than Once or twice Three or more
past month_____ once a week_____ a week_____ times a week_____

e) Other restlessness while you sleep; please describe____________________________________

© 1989, University of Pittsburgh. All rights reserved. Developed by Buysse,D.J., Reynolds,C.F.,
Monk,T.H., Berman,S.R., and
Kupfer,D.J. of the University of Pittsburgh using National Institute of Mental Health Funding.
past month____ once a week_____ a week_____ times a week_____

16.1.11.2 Leeds Sleep Evaluation Questionnaire

How would you describe the way you currently fall asleep in comparison to usual?
1. More difficult than usual __________________________ Easier than usual
2. Slower than usual _______________________ More quickly than usual
3. I feel less sleepy than usual ________________ More sleepy than usual

How would you describe the quality of your sleep compared to normal sleep?
4. More restless than usual __________________________ Calmer than usual
5. With more wakeful periods than usual ___________________________ With less wakeful periods than usual

How would you describe your awakening in comparison to usual?
6. More difficult than usual ______________________________ Easier than usual
7. Requires a period of time longer than usual ___________________________ Shorter than usual

How do you feel when you wake up?
8. Tired ____________________________ Alert

How do you feel now?
9. Tired ____________________________ Alert

How would you describe your balance and co-ordination upon awakening?
10. More disrupted than usual __________________________ Less disrupted than usual

16.1.11.3 Epworth-Sleepiness Scale
How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? This refers to your usual way of life in recent times. Even if you have not done some of these things recently try to work out how they would have affected you. Use the following scale to choose the most appropriate number for each situation:

<p>| 0 = no chance of dozing |
| 1 = slight chance of dozing |
| 2 = moderate chance of dozing |
| 3 = high chance of dozing |</p>
<table>
<thead>
<tr>
<th>SITUATION</th>
<th>CHANCE OF DOZING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitting and reading</td>
<td>________</td>
</tr>
<tr>
<td>Watching TV</td>
<td>________</td>
</tr>
<tr>
<td>Sitting inactive in a public place (e.g. a theater or a meeting)</td>
<td>________</td>
</tr>
<tr>
<td>As a passenger in a car for an hour without a break</td>
<td>________</td>
</tr>
<tr>
<td>Lying down to rest in the afternoon when circumstances permit</td>
<td>________</td>
</tr>
<tr>
<td>Sitting and talking to someone</td>
<td>________</td>
</tr>
<tr>
<td>Sitting quietly after a lunch without alcohol</td>
<td>________</td>
</tr>
<tr>
<td>In a car, while stopped for a few minutes in traffic</td>
<td>________</td>
</tr>
</tbody>
</table>

**TOTAL SCORE = _______________________**

**Score Results:**

1-6 Congratulations, you are getting enough sleep!
7-8 Your score is average
9 and up Very sleepy and should seek medical advice

16.2 Subject data listings

Sleep Analog data:

<table>
<thead>
<tr>
<th>Subject #</th>
<th>Initial</th>
<th>After 2 weeks</th>
<th>Final</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>5.5</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>6</td>
<td>6.5</td>
</tr>
<tr>
<td>7</td>
<td>4</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>12</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>13</td>
<td>3</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>15</td>
<td>5</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>19</td>
<td>2</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>22</td>
<td>4.5</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>23</td>
<td>Dropped</td>
<td>Dropped</td>
<td>Dropped</td>
</tr>
<tr>
<td>25</td>
<td>Dropped</td>
<td>Dropped</td>
<td>Dropped</td>
</tr>
<tr>
<td>26</td>
<td>4</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>28</td>
<td>5</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>30</td>
<td>3</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>31</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>33</td>
<td>5</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>35</td>
<td>4</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>38</td>
<td>4</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>39</td>
<td>5</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>43</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>44</td>
<td>4</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>46</td>
<td>4</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>47</td>
<td>3</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>50</td>
<td>3</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>Subject #</td>
<td>Initial</td>
<td>After 2 weeks</td>
<td>Final</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>---------------</td>
<td>-------</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>5.5</td>
<td>5.5</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>7</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>4</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>14</td>
<td>1</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>16</td>
<td>2</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>17</td>
<td>Dropped</td>
<td>Dropped</td>
<td>Dropped</td>
</tr>
<tr>
<td>18</td>
<td>5</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>20</td>
<td>4</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>21</td>
<td>3</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>24</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>27</td>
<td>1</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>29</td>
<td>Dropped</td>
<td>Dropped</td>
<td>Dropped</td>
</tr>
<tr>
<td>32</td>
<td>4</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>34</td>
<td>4</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>36</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>37</td>
<td>5</td>
<td>5.5</td>
<td>6.5</td>
</tr>
<tr>
<td>40</td>
<td>3</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>41</td>
<td>5</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>42</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>45</td>
<td>5</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>48</td>
<td>5</td>
<td>5</td>
<td>7.5</td>
</tr>
<tr>
<td>49</td>
<td>5</td>
<td>5</td>
<td>8</td>
</tr>
</tbody>
</table>
16.3 Case report forms

16.3.1 CRFs of deaths, other serious adverse events and withdrawals for AE
Not applicable.

16.3.2 Other CRFs submitted
Not applicable.

16.4 Other Individual subject data listings (US Archival Listings)
Not applicable.